Unknown PHASE1 INTERVENTIONAL 1-arm NCT05942378

A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors

A Phase 1 Study to Evaluate the Efficacy and Safety of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors

Sponsor: Fudan University

Conditions Advanced Solid Tumors

Interventions Adebrelimab HRXG-K-1939

Updated 4 times since 2023 Last updated: Jul 4, 2023 Started: Jul 1, 2023 Primary completion: Sep 1, 2025 Completion: Dec 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05942378, this PHASE1 trial focuses on Advanced Solid Tumors and remains ongoing. Sponsored by Fudan University, it has been updated 4 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE1

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jan 2026 [monthly]

Not Yet Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1
Aug 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jul 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China